Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent

06-Sep-2007

Oncolytics Biotech Inc. announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated cancers from developing drug resistance to chemotherapeutic agents.

"Recent research conducted by the U.S. National Cancer Institute (NCI) and Cornell University demonstrated that administering reovirus in combination with various chemotherapeutic agents potentiates, or enhances tumour-killing, thus preventing the cancer cells from developing drug resistance," said Dr. Matt Coffey, Chief Scientific Officer. "This patent complements the combination REOLYSIN(R) and chemotherapy clinical program that we are pursuing in the U.K."

Other news from the department research and development

Most read news

More news from our other portals

Vis-à-Vis with UV/VIS